For lupus-related joint involvement, both peptides address different aspects of tissue damage and inflammation
The FDA has classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding, such as immunogenicity, impurities, and insufficient safety evidence for suggested administration routes
"The sale of these products together demonstrates that you intend for your 'Bacteriostatic Water' to be used in combination for injection
You cant escape it on your social media feeds. On the lack of safety and efficacy data for BPC-157 Jarry: Ill give you an example of one which is quite popular
Do not use or quote any of these information for commercial purposes, these information are only for internal study.
SIRT1 and PGC-1 expression levels were decreased in rat MI/R groups, but were significantly increased after treatment with Que (Tang et al., 2019)